iifl-logo-icon 1

Zydus Lifesciences Ltd Profit & Loss Statement

945.6
(1.24%)
Feb 13, 2025|02:29:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

7,981.9

7,780

6,347.4

5,809.9

yoy growth (%)

2.59

22.56

9.25

79.83

Raw materials

-2,870.2

-2,351.4

-1,951.7

-1,695.7

As % of sales

35.95

30.22

30.74

29.18

Employee costs

-1,204.9

-1,147.3

-1,077.4

-826

As % of sales

15.09

14.74

16.97

14.21

Other costs

-1,988.7

-1,972.6

-1,895.2

-1,641.9

As % of sales (Other Cost)

24.91

25.35

29.85

28.26

Operating profit

1,918.1

2,308.7

1,423.1

1,646.3

OPM

24.03

29.67

22.42

28.33

Depreciation

-478.7

-451.1

-428.9

-293.1

Interest expense

-134.9

-70.9

-233.9

-63.9

Other income

178.7

89.3

849.4

207.9

Profit before tax

1,483.2

1,876

1,609.7

1,497.2

Taxes

-306

-212.3

-204.1

-406.4

Tax rate

-20.63

-11.31

-12.67

-27.14

Minorities and other

0

0

59.3

0

Adj. profit

1,177.2

1,663.7

1,464.9

1,090.8

Exceptional items

-319.3

-187.5

-52

0

Net profit

857.9

1,476.2

1,412.9

1,090.8

yoy growth (%)

-41.88

4.48

29.52

64.79

NPM

10.74

18.97

22.25

18.77

Zydus Lifesci. : related Articles

Zydus Lifesciences Reports 20% Revenue Jump, 14% Profit Rise in Q2
12 Nov 2024|03:48 PM

EBITDA for Q2 increased by 27.5% year-on-year to ₹1,461.4 crore, with EBITDA margins expanding by 170 basis points to 27.9%.

Read More
Top 10 stocks for today - 15th October 2024
15 Oct 2024|08:54 AM

Here are some of the stocks that may see significant price movement today: Reliance Industries, HCLTech, Sunteck Realty, etc.

Read More
Zydus Gets US Nod for Generic Schizophrenia Drug
11 Oct 2024|12:52 PM

According to a regulatory filing by Zydus Lifesciences, the USFDA approved Paliperidone extended-release tablets.

Read More
Zydus Lifesciences gets USFDA nod for prostate cancer drug
3 Oct 2024|01:11 PM

Patients with metastatic castration-sensitive prostate cancer and castration-resistant prostate cancer are recommended to be treated with enzalutamide tablets.

Read More
Zydus Lifesciences Acquires Sterling Biotech's API Business for ₹84 Crore
18 Sep 2024|11:24 AM

The purchase will be on a slump sale basis, treating it as a going concern, with a cash-free and debt-free transaction at a lump-sum consideration of ₹840 million.

Read More
Zydus Partners with Viwit for $237M US Market Entry with MRI Contrast Agents
16 Sep 2024|03:58 PM

Zydus will take charge of marketing, distributing, and selling these MRI contrast agents in the US market, marking its entry into the contrast agent product category.

Read More
USFDA Warns Zydus Lifesciences for Manufacturing Violations
16 Sep 2024|03:43 PM

The warning letter specifically cites Zydus’s failure to properly investigate contamination issues in drug products at its Jarod plant in Vadodara district.

Read More
Top 10 stocks for today – 16th September, 2024
16 Sep 2024|08:38 AM

Here are some of the stocks that may see significant price movement today: Adani Power & Adani Green, Hindustan Unilever, Dixon Technologies, etc.

Read More
Zydus Life’s Jarod plant gets USFDA warning letter
12 Sep 2024|03:28 PM

As per USFDA, the facility did not thoroughly analyse contamination across medicine batches and continued to issue compromised items.

Read More
Zydus Lifesciences' Usnoflast Shows Promise in ALS Phase II(a) Trial
11 Sep 2024|11:00 AM

Usnoflast is a new NLRP3 inhibitor showing promise in the Phase II(a) trial, offering hope for ALS patients, a disease characterized by severe inflammation and rapid muscle control loss.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.